Updated : Mar 07, 2020 in Spiritual


The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.

Author: Dounris Douzshura
Country: Angola
Language: English (Spanish)
Genre: Music
Published (Last): 20 September 2004
Pages: 178
PDF File Size: 17.44 Mb
ePub File Size: 10.6 Mb
ISBN: 597-4-89303-880-2
Downloads: 81947
Price: Free* [*Free Regsitration Required]
Uploader: Vorg

An I ntervention T rial E valuating R osuvastatin trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels. We randomly assigned 17, apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less jypiter mg per deciliter 3.


The trial was stopped after a median follow-up of 1. Compared to patients taking a placebopatients given rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0. The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin. Consistent effects were observed in all subgroups evaluated. By using this site, you agree to the Terms of Use and Privacy Policy.

The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes. Views Read Edit View history.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Comment in Ann Intern Med. Results, Controversies, and Implications for Prevention”. On the role of C-reactive protein, a study employing Mendelian randomizationpublished in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular disease; the results may argue against CRP’s use as a marker of cardiovascular disease risk or for identifying subjects for statin therapy as in JUPITER, and more jejm argue against using CRP as a therapeutic target per se.


The trial analyzed 17, patients without evidence of heart bejm but with high CRP levels.

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Retrieved from ” https: There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin values in hupiter rosuvastatin group, an effect that has also been seen in studies with other statins.

They concluded that, “The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors. N Engl J Med.

JUPITER trial – Wikipedia

Because half of all vascular events occur in patients with normal or low levels of LDL cholesterol, JUPITER was designed to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them. Michel de Lorgeril, et al. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP.


Retrieved July 1, Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

The trial was stopped early, after just 1. They also raised concerns about conflict of interest in the trial design and leadership: JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.

Inresults presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events.

Cleve Clin J Med. The article’s authors critiqued what they saw as flaws in the trial, pointing out that the cardiovascular mortality rate and the case-fatality rate for myocardial infarction were much lower than they expected. This page was last edited on 4 Novemberat The rates of the primary end point were 0. Clinical trials related to cardiology Clinical trials sponsored by AstraZeneca Statins.

Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. Am J Kidney Dis.

Cardiovascular Quality and Outcomes. From Wikipedia, the free encyclopedia.